{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:08:54Z","timestamp":1790089734302,"version":"4.0.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"DOI":"10.1038\/s41401-026-01921-7","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:48:15Z","timestamp":1790088495000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Niclosamide suppresses breast cancer progression and enhances paclitaxel sensitivity by targeting the ATP6AP1-YY1-XIAP axis"],"prefix":"10.1038","author":[{"given":"Xin-yuan","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-ya","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-jun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-long","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-ning","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-gui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-yuan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"1921_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019;5:66. https:\/\/doi.org\/10.1038\/s41572-019-0111-2.","journal-title":"Nat Rev Dis Primers"},{"key":"1921_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1921_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106535","volume":"84","author":"K Barzaman","year":"2020","unstructured":"Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, et al. Breast cancer: biology, biomarkers, and treatments. Int Immunopharmacol. 2020;84:106535. https:\/\/doi.org\/10.1016\/j.intimp.2020.106535.","journal-title":"Int Immunopharmacol"},{"key":"1921_CR4","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20202537","volume":"40","author":"Q Wang","year":"2020","unstructured":"Wang Q, Zhao S, Gan L, Zhuang Z. Bioinformatics analysis of prognostic value of PITX1 gene in breast cancer. Biosci Rep. 2020;40:BSR20202537. https:\/\/doi.org\/10.1042\/BSR20202537.","journal-title":"Biosci Rep"},{"key":"1921_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218192","volume":"639","author":"F Duan","year":"2026","unstructured":"Duan F, Zhang C, Wu Z, Zhuang L, Zou Y, Wang X, et al. Copper orchestrates triple-negative breast cancer progression via the STEAP3-dependent CDK16-JAK1 activation. Cancer Lett. 2026;639:218192. https:\/\/doi.org\/10.1016\/j.canlet.2025.218192.","journal-title":"Cancer Lett"},{"key":"1921_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2020.183341","volume":"1862","author":"MP Collins","year":"2020","unstructured":"Collins MP, Forgac M. Regulation and function of V-ATPases in physiology and disease. Biochim Biophys Acta Biomembr. 2020;1862:183341. https:\/\/doi.org\/10.1016\/j.bbamem.2020.183341.","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"1921_CR7","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41417-022-00477-y","volume":"29","author":"F Chen","year":"2022","unstructured":"Chen F, Kang R, Liu J, Tang D. The V-ATPases in cancer and cell death. Cancer Gene Ther. 2022;29:1529\u201341. https:\/\/doi.org\/10.1038\/s41417-022-00477-y.","journal-title":"Cancer Gene Ther"},{"key":"1921_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.tibs.2019.12.007","volume":"45","author":"T Vasanthakumar","year":"2020","unstructured":"Vasanthakumar T, Rubinstein JL. Structure and roles of V-type ATPases. Trends Biochem Sci. 2020;45:295\u2013307. https:\/\/doi.org\/10.1016\/j.tibs.2019.12.007.","journal-title":"Trends Biochem Sci"},{"key":"1921_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.14670\/HH-22.443","volume":"22","author":"J Xu","year":"2007","unstructured":"Xu J, Cheng T, Feng HT, Pavlos NJ, Zheng MH. Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis. Histol Histopathol. 2007;22:443\u201354. https:\/\/doi.org\/10.14670\/HH-22.443.","journal-title":"Histol Histopathol"},{"key":"1921_CR10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nrm729","volume":"3","author":"T Nishi","year":"2002","unstructured":"Nishi T, Forgac M. The vacuolar (H+)-ATPases are nature\u2019s most versatile proton pumps. Nat Rev Mol Cell Biol. 2002;3:94\u2013103. https:\/\/doi.org\/10.1038\/nrm729.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1921_CR11","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nrm2272","volume":"8","author":"M Forgac","year":"2007","unstructured":"Forgac M. Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol. 2007;8:917\u201329. https:\/\/doi.org\/10.1038\/nrm2272.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1921_CR12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1152\/physiol.00007.2013","volume":"28","author":"S Breton","year":"2013","unstructured":"Breton S, Brown D. Regulation of luminal acidification by the V-ATPase. Physiol Bethesda Md. 2013;28:318\u201329. https:\/\/doi.org\/10.1152\/physiol.00007.2013.","journal-title":"Physiol Bethesda Md"},{"key":"1921_CR13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2741\/4506","volume":"22","author":"C McGuire","year":"2017","unstructured":"McGuire C, Stransky L, Cotter K, Forgac M. Regulation of V-ATPase activity. Front Biosci Landmark Ed. 2017;22:609\u201322. https:\/\/doi.org\/10.2741\/4506.","journal-title":"Front Biosci Landmark Ed"},{"key":"1921_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05886-y","volume":"9","author":"F Pareja","year":"2018","unstructured":"Pareja F, Brandes AH, Basili T, Selenica P, Geyer FC, Fan D, et al. Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. Nat Commun. 2018;9:3533. https:\/\/doi.org\/10.1038\/s41467-018-05886-y.","journal-title":"Nat Commun"},{"key":"1921_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1021\/pr100686b","volume":"10","author":"KS Anderson","year":"2011","unstructured":"Anderson KS, Sibani S, Wallstrom G, Qiu J, Mendoza EA, Raphael J, et al. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res. 2011;10:85\u201396. https:\/\/doi.org\/10.1021\/pr100686b.","journal-title":"J Proteome Res"},{"key":"1921_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.958290","volume":"13","author":"Y Tian","year":"2022","unstructured":"Tian Y, Gao M, Huang L, Zhou H, Wang J. ATP6AP1 is a potential prognostic biomarker and is associated with iron metabolism in breast cancer. Front Genet. 2022;13:958290. https:\/\/doi.org\/10.3389\/fgene.2022.958290.","journal-title":"Front Genet"},{"key":"1921_CR17","first-page":"5","volume":"29","author":"S L\u2019Esp\u00e9rance","year":"2006","unstructured":"L\u2019Esp\u00e9rance S, Popa I, Bachvarova M, Plante M, Patten N, Wu L, et al. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol. 2006;29:5\u201324.","journal-title":"Int J Oncol"},{"key":"1921_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-54437-7","volume":"14","author":"S Zhang","year":"2024","unstructured":"Zhang S, Wang Y, Zhang X, Wang M, Wu H, Tao Y, et al. ATP6AP1 as a potential prognostic biomarker in CRC by comprehensive analysis and verification. Sci Rep. 2024;14:4018. https:\/\/doi.org\/10.1038\/s41598-024-54437-7.","journal-title":"Sci Rep"},{"key":"1921_CR19","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1002\/j.1460-2075.1996.tb00629.x","volume":"15","author":"CS Duckett","year":"1996","unstructured":"Duckett CS, Nava VE, Gedrich RW, Clem RJ, Van Dongen JL, Gilfillan MC, et al. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. EMBO J. 1996;15:2685\u201394.","journal-title":"EMBO J"},{"key":"1921_CR20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10495-022-01734-z","volume":"27","author":"M Hanifeh","year":"2022","unstructured":"Hanifeh M, Ataei F. XIAP as a multifaceted molecule in cellular signaling. Apoptosis Int J Program Cell Death. 2022;27:441\u201353. https:\/\/doi.org\/10.1007\/s10495-022-01734-z.","journal-title":"Apoptosis Int J Program Cell Death"},{"key":"1921_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-019-0181-8","volume":"8","author":"J Xu","year":"2019","unstructured":"Xu J, Hua X, Yang R, Jin H, Li J, Zhu J, et al. XIAP interacts with E2F1 and Sp1 via its BIR2 and BIR3 domains, specifically activating MMP2 to promote bladder cancer invasion. Oncogenesis. 2019;8:71. https:\/\/doi.org\/10.1038\/s41389-019-0181-8.","journal-title":"Oncogenesis"},{"key":"1921_CR22","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.bbrc.2010.02.084","volume":"393","author":"YJ Kang","year":"2010","unstructured":"Kang YJ, Jang M, Park YK, Kang S, Bae K-H, Cho S, et al. Molecular interaction between HAX-1 and XIAP inhibits apoptosis. Biochem Biophys Res Commun. 2010;393:794\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2010.02.084.","journal-title":"Biochem Biophys Res Commun"},{"key":"1921_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.311","volume":"7","author":"S Wicki","year":"2016","unstructured":"Wicki S, Gurzeler U, Wei-Lynn Wong W, Jost PJ, Bachmann D, Kaufmann T. Loss of XIAP facilitates switch to TNF\u03b1-induced necroptosis in mouse neutrophils. Cell Death Dis. 2016;7:e2422. https:\/\/doi.org\/10.1038\/cddis.2016.311.","journal-title":"Cell Death Dis"},{"key":"1921_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s12032-014-0108-3","volume":"31","author":"W-Y Wu","year":"2014","unstructured":"Wu W-Y, Kim H, Zhang C-L, Meng X-L, Wu Z-S. Clinical significance of autophagic protein LC3 levels and its correlation with XIAP expression in hepatocellular carcinoma. Med Oncol Northwood Lond Engl. 2014;31:108. https:\/\/doi.org\/10.1007\/s12032-014-0108-3.","journal-title":"Med Oncol Northwood Lond Engl"},{"key":"1921_CR25","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1038\/emboj.2013.133","volume":"32","author":"X Huang","year":"2013","unstructured":"Huang X, Wu Z, Mei Y, Wu M. XIAP inhibits autophagy via XIAP-Mdm2-p53 signalling. EMBO J. 2013;32:2204\u201316. https:\/\/doi.org\/10.1038\/emboj.2013.133.","journal-title":"EMBO J"},{"key":"1921_CR26","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.3389\/fonc.2019.01230","volume":"9","author":"S Sarvagalla","year":"2019","unstructured":"Sarvagalla S, Kolapalli SP, Vallabhapurapu S. The two sides of YY1 in cancer: a friend and a foe. Front Oncol. 2019;9:1230. https:\/\/doi.org\/10.3389\/fonc.2019.01230.","journal-title":"Front Oncol"},{"key":"1921_CR27","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.7150\/thno.43481","volume":"10","author":"ITS Meliala","year":"2020","unstructured":"Meliala ITS, Hosea R, Kasim V, Wu S. The biological implications of Yin Yang 1 in the hallmarks of cancer. Theranostics. 2020;10:4183\u2013200. https:\/\/doi.org\/10.7150\/thno.43481.","journal-title":"Theranostics"},{"key":"1921_CR28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/cbr.2019.2779","volume":"34","author":"L Chen","year":"2019","unstructured":"Chen L, Gong X, Huang M. YY1-Activated long noncoding RNA SNHG5 promotes glioblastoma cell proliferation through p38\/MAPK signaling pathway. Cancer Biother Radiopharm. 2019;34:589\u201396. https:\/\/doi.org\/10.1089\/cbr.2019.2779.","journal-title":"Cancer Biother Radiopharm"},{"key":"1921_CR29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13046-015-0177-y","volume":"34","author":"G Zhao","year":"2015","unstructured":"Zhao G, Li Q, Wang A, Jiao J. YY1 regulates melanoma tumorigenesis through a miR-9\u2009~\u2009RYBP axis. J Exp Clin Cancer Res CR. 2015;34:66. https:\/\/doi.org\/10.1186\/s13046-015-0177-y.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"1921_CR30","doi-asserted-by":"publisher","first-page":"e66121","DOI":"10.1371\/journal.pone.0066121","volume":"8","author":"V Potluri","year":"2013","unstructured":"Potluri V, Noothi SK, Vallabhapurapu SD, Yoon S-O, Driscoll JJ, Lawrie CH, et al. Transcriptional repression of Bim by a novel YY1-RelA complex is essential for the survival and growth of multiple myeloma. PLoS One. 2013;8:e66121. https:\/\/doi.org\/10.1371\/journal.pone.0066121.","journal-title":"PLoS One"},{"key":"1921_CR31","doi-asserted-by":"publisher","first-page":"18415","DOI":"10.1002\/jcb.29158","volume":"120","author":"F Liang","year":"2019","unstructured":"Liang F, Fu X, Wang L. miR-5590-3p-YY1 feedback loop promotes the proliferation and migration of triple-negative breast cancer cells. J Cell Biochem. 2019;120:18415\u201324. https:\/\/doi.org\/10.1002\/jcb.29158.","journal-title":"J Cell Biochem"},{"key":"1921_CR32","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1158\/0008-5472.CAN-18-2238","volume":"79","author":"J Han","year":"2019","unstructured":"Han J, Meng J, Chen S, Wang X, Yin S, Zhang Q, et al. YY1 complex promotes quaking expression via super-enhancer binding during EMT of hepatocellular carcinoma. Cancer Res. 2019;79:1451\u201364. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-2238.","journal-title":"Cancer Res"},{"key":"1921_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2174\/1568009615666150131124200","volume":"15","author":"J Shi","year":"2015","unstructured":"Shi J, Hao A, Zhang Q, Sui G. The role of YY1 in oncogenesis and its potential as a drug target in cancer therapies. Curr Cancer Drug Targets. 2015;15:145\u201357. https:\/\/doi.org\/10.2174\/1568009615666150131124200.","journal-title":"Curr Cancer Drug Targets"},{"key":"1921_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/CritRevOncog.2017021314","volume":"22","author":"W Wang","year":"2017","unstructured":"Wang W, Li D, Sui G. YY1 is an inducer of cancer metastasis. Crit Rev Oncog. 2017;22:1\u201311. https:\/\/doi.org\/10.1615\/CritRevOncog.2017021314.","journal-title":"Crit Rev Oncog"},{"key":"1921_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.drup.2019.04.001","volume":"43","author":"E Hays","year":"2019","unstructured":"Hays E, Bonavida B. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. Drug Resist Update. 2019;43:10\u201328. https:\/\/doi.org\/10.1016\/j.drup.2019.04.001.","journal-title":"Drug Resist Update"},{"key":"1921_CR36","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.3390\/cancers15133506","volume":"15","author":"R Hosea","year":"2023","unstructured":"Hosea R, Hillary S, Wu S, Kasim V. Targeting transcription factor YY1 for cancer treatment: current strategies and future directions. Cancers. 2023;15:3506. https:\/\/doi.org\/10.3390\/cancers15133506.","journal-title":"Cancers"},{"key":"1921_CR37","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98\u2013102. https:\/\/doi.org\/10.1093\/nar\/gkx247.","journal-title":"Nucleic Acids Res"},{"key":"1921_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n M, Fagerberg L, Hallstr\u00f6m BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics tissue-based map of the human proteome. Science. 2015;347:1260419. https:\/\/doi.org\/10.1126\/science.1260419.","journal-title":"Science"},{"key":"1921_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan2507","volume":"357","author":"M Uhlen","year":"2017","unstructured":"Uhlen M, Zhang C, Lee S, Sj\u00f6stedt E, Fagerberg L, Bidkhori G, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357:eaan2507. https:\/\/doi.org\/10.1126\/science.aan2507.","journal-title":"Science"},{"key":"1921_CR40","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/pro.3307","volume":"27","author":"PJ Thul","year":"2018","unstructured":"Thul PJ, Lindskog C. The human protein atlas: a spatial map of the human proteome. Protein Sci Publ Protein Soc. 2018;27:233\u201344. https:\/\/doi.org\/10.1002\/pro.3307.","journal-title":"Protein Sci Publ Protein Soc"},{"key":"1921_CR41","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","volume":"15","author":"Y Huang","year":"2022","unstructured":"Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol OncolJ Hematol Oncol. 2022;15:129. https:\/\/doi.org\/10.1186\/s13045-022-01347-8.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"1921_CR42","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","volume":"29","author":"I Pastushenko","year":"2019","unstructured":"Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29:212\u201326. https:\/\/doi.org\/10.1016\/j.tcb.2018.12.001.","journal-title":"Trends Cell Biol"},{"key":"1921_CR43","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/biom9120789","volume":"9","author":"TM Abu Samaan","year":"2019","unstructured":"Abu Samaan TM, Samec M, Liskova A, Kubatka P, B\u00fcsselberg D. Paclitaxel\u2019s mechanistic and clinical effects on breast cancer. Biomolecules. 2019;9:789. https:\/\/doi.org\/10.3390\/biom9120789.","journal-title":"Biomolecules"},{"key":"1921_CR44","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","volume":"9","author":"G Zhong","year":"2024","unstructured":"Zhong G, Chang X, Xie W, Zhou X. Targeted protein degradation: advances in drug discovery and clinical practice. Signal Transduct Target Ther. 2024;9:308. https:\/\/doi.org\/10.1038\/s41392-024-02004-x.","journal-title":"Signal Transduct Target Ther"},{"key":"1921_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104178","volume":"29","author":"D Pliatsika","year":"2024","unstructured":"Pliatsika D, Blatter C, Riedl R. Targeted protein degradation: current molecular targets, localization, and strategies. Drug Discov Today. 2024;29:104178. https:\/\/doi.org\/10.1016\/j.drudis.2024.104178.","journal-title":"Drug Discov Today"},{"key":"1921_CR46","doi-asserted-by":"publisher","first-page":"549","DOI":"10.26444\/aaem\/75943","volume":"24","author":"A Kolak","year":"2017","unstructured":"Kolak A, Kami\u0144ska M, Sygit K, Budny A, Surdyka D, Kukie\u0142ka-Budny B, et al. Primary and secondary prevention of breast cancer. Ann Agric Environ Med AAEM. 2017;24:549\u201353. https:\/\/doi.org\/10.26444\/aaem\/75943.","journal-title":"Ann Agric Environ Med AAEM"},{"key":"1921_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2021.0459","volume":"83","author":"C Katsura","year":"2022","unstructured":"Katsura C, Ogunmwonyi I, Kankam HK, Saha S. Breast cancer: presentation, investigation and management. Br J Hosp Med Lond Engl. 2005. 2022;83:1\u20137. https:\/\/doi.org\/10.12968\/hmed.2021.0459.","journal-title":"Br J Hosp Med Lond Engl. 2005"},{"key":"1921_CR48","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.32604\/or.2025.068292","volume":"33","author":"S Duan","year":"2025","unstructured":"Duan S, Li X, Song C, Wu S, Tang Y, Bao Q, et al. Isoliquiritigenin inhibits triple-negative breast cancer progression via targeting the IRF5\/SLC7A5\/IDO1-mediated tryptophan metabolism pathway. Oncol Res. 2025;33:3543\u201356. https:\/\/doi.org\/10.32604\/or.2025.068292.","journal-title":"Oncol Res"},{"key":"1921_CR49","doi-asserted-by":"publisher","DOI":"10.34133\/research.0854","volume":"8","author":"J Zhang","year":"2025","unstructured":"Zhang J, Huang Z, Song C, Wu S, Xie J, Zou Y, et al. PRMT1-mediated PARP1 methylation drives lung metastasis and chemoresistance via P65 activation in triple-negative breast cancer. Research. 2025;8:0854. https:\/\/doi.org\/10.34133\/research.0854.","journal-title":"Research"},{"key":"1921_CR50","doi-asserted-by":"publisher","first-page":"C1443","DOI":"10.1152\/ajpcell.00407.2003","volume":"286","author":"SR Sennoune","year":"2004","unstructured":"Sennoune SR, Bakunts K, Mart\u00ednez GM, Chua-Tuan JL, Kebir Y, Attaya MN, et al. Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol. 2004;286:C1443\u20131452. https:\/\/doi.org\/10.1152\/ajpcell.00407.2003.","journal-title":"Am J Physiol Cell Physiol"},{"key":"1921_CR51","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.bbadis.2013.04.003","volume":"1832","author":"S Avnet","year":"2013","unstructured":"Avnet S, Di Pompo G, Lemma S, Salerno M, Perut F, Bonuccelli G, et al. V-ATPase is a candidate therapeutic target for Ewing sarcoma. Biochim Biophys Acta. 2013;1832:1105\u201316. https:\/\/doi.org\/10.1016\/j.bbadis.2013.04.003.","journal-title":"Biochim Biophys Acta"},{"key":"1921_CR52","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/labinvest.2011.8","volume":"91","author":"C Chung","year":"2011","unstructured":"Chung C, Mader CC, Schmitz JC, Atladottir J, Fitchev P, Cornwell ML, et al. The vacuolar-ATPase modulates matrix metalloproteinase isoforms in human pancreatic cancer. Lab Invest. 2011;91:732\u201343. https:\/\/doi.org\/10.1038\/labinvest.2011.8.","journal-title":"Lab Invest"},{"key":"1921_CR53","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/1746-1596-7-180","volume":"7","author":"L Huang","year":"2012","unstructured":"Huang L, Lu Q, Han Y, Li Z, Zhang Z, Li X. ABCG2\/V-ATPase was associated with the drug resistance and tumor metastasis of esophageal squamous cancer cells. Diagn Pathol. 2012;7:180. https:\/\/doi.org\/10.1186\/1746-1596-7-180.","journal-title":"Diagn Pathol"},{"key":"1921_CR54","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.18632\/oncotarget.2902","volume":"6","author":"A Kulshrestha","year":"2015","unstructured":"Kulshrestha A, Katara GK, Ibrahim S, Pamarthy S, Jaiswal MK, Gilman Sachs A, et al. Vacuolar ATPase \u201ca2\u201d isoform exhibits distinct cell surface accumulation and modulates matrix metalloproteinase activity in ovarian cancer. Oncotarget. 2015;6:3797\u2013810. https:\/\/doi.org\/10.18632\/oncotarget.2902.","journal-title":"Oncotarget"},{"key":"1921_CR55","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/1746-1596-8-145","volume":"8","author":"Q Lu","year":"2013","unstructured":"Lu Q, Lu S, Huang L, Wang T, Wan Y, Zhou CX, et al. The expression of V-ATPase is associated with drug resistance and pathology of non-small-cell lung cancer. Diagn Pathol. 2013;8:145. https:\/\/doi.org\/10.1186\/1746-1596-8-145.","journal-title":"Diagn Pathol"},{"key":"1921_CR56","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/ijc.27811","volume":"132","author":"V Michel","year":"2013","unstructured":"Michel V, Licon-Mu\u00f1oz Y, Trujillo K, Bisoffi M, Parra KJ. Inhibitors of vacuolar ATPase proton pumps inhibit human prostate cancer cell invasion and prostate-specific antigen expression and secretion. Int J Cancer. 2013;132:E1\u201310. https:\/\/doi.org\/10.1002\/ijc.27811.","journal-title":"Int J Cancer"},{"key":"1921_CR57","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1158\/1541-7786.MCR-10-0449","volume":"9","author":"T Nishisho","year":"2011","unstructured":"Nishisho T, Hata K, Nakanishi M, Morita Y, Sun-Wada G-H, Wada Y, et al. The a3 isoform vacuolar type H+-ATPase promotes distant metastasis in the mouse B16 melanoma cells. Mol Cancer Res MCR. 2011;9:845\u201355. https:\/\/doi.org\/10.1158\/1541-7786.MCR-10-0449.","journal-title":"Mol Cancer Res MCR"},{"key":"1921_CR58","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1093\/carcin\/bgs277","volume":"33","author":"J Xu","year":"2012","unstructured":"Xu J, Xie R, Liu X, Wen G, Jin H, Yu Z, et al. Expression and functional role of vacuolar H+-ATPase in human hepatocellular carcinoma. Carcinogenesis. 2012;33:2432\u201340. https:\/\/doi.org\/10.1093\/carcin\/bgs277.","journal-title":"Carcinogenesis"},{"key":"1921_CR59","doi-asserted-by":"publisher","first-page":"16904","DOI":"10.18632\/aging.203229","volume":"13","author":"J Wang","year":"2021","unstructured":"Wang J, Liu Y, Zhang S. Prognostic and immunological value of ATP6AP1 in breast cancer: implications for SARS-CoV-2. Aging. 2021;13:16904\u201321. https:\/\/doi.org\/10.18632\/aging.203229.","journal-title":"Aging"},{"key":"1921_CR60","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.3390\/ijms21124392","volume":"21","author":"J Hrab\u011bta","year":"2020","unstructured":"Hrab\u011bta J, Belhajov\u00e1 M, \u0160ubrtov\u00e1 H, Merlos Rodrigo MA, Heger Z, Eckschlager T. Drug sequestration in lysosomes as one of the mechanisms of chemoresistance of cancer cells and the possibilities of its inhibition. Int J Mol Sci. 2020;21:4392. https:\/\/doi.org\/10.3390\/ijms21124392.","journal-title":"Int J Mol Sci"},{"key":"1921_CR61","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41\u201358. https:\/\/doi.org\/10.1038\/nrd.2018.168.","journal-title":"Nat Rev Drug Discov"},{"key":"1921_CR62","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/j.jhep.2021.01.024","volume":"75","author":"P Caraceni","year":"2021","unstructured":"Caraceni P, Abraldes JG, Gin\u00e8s P, Newsome PN, Sarin SK. The search for disease-modifying agents in decompensated cirrhosis: from drug repurposing to drug discovery. J Hepatol. 2021;75:S118\u201334. https:\/\/doi.org\/10.1016\/j.jhep.2021.01.024.","journal-title":"J Hepatol"},{"key":"1921_CR63","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41581-024-00864-8","volume":"20","author":"MSY Ng","year":"2024","unstructured":"Ng MSY, Kaur G, Francis RS, Hawley CM, Johnson DW. Drug repurposing for glomerular diseases: an underutilized resource. Nat Rev Nephrol. 2024;20:707\u201321. https:\/\/doi.org\/10.1038\/s41581-024-00864-8.","journal-title":"Nat Rev Nephrol"},{"key":"1921_CR64","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","volume":"5","author":"M-Z Jin","year":"2020","unstructured":"Jin MZ, Jin WL. The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020;5:166. https:\/\/doi.org\/10.1038\/s41392-020-00280-x.","journal-title":"Signal Transduct Target Ther"},{"key":"1921_CR65","doi-asserted-by":"publisher","first-page":"e667","DOI":"10.1016\/S2589-7500(20)30192-8","volume":"2","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Wang F, Tang J, Nussinov R, Cheng F. Artificial intelligence in COVID-19 drug repurposing. Lancet Digital Health. 2020;2:e667\u201376. https:\/\/doi.org\/10.1016\/S2589-7500(20)30192-8.","journal-title":"Lancet Digital Health"},{"key":"1921_CR66","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1109\/TNNLS.2021.3111745","volume":"32","author":"CY Lee","year":"2021","unstructured":"Lee CY, Chen YPP. New insights into drug repurposing for COVID-19 using deep learning. IEEE Trans Neural Netw Learn Syst. 2021;32:4770\u201380. https:\/\/doi.org\/10.1109\/TNNLS.2021.3111745.","journal-title":"IEEE Trans Neural Netw Learn Syst"},{"key":"1921_CR67","doi-asserted-by":"publisher","first-page":"16116","DOI":"10.3390\/ijms232416116","volume":"23","author":"Z Wang","year":"2022","unstructured":"Wang Z, Ren J, Du J, Wang H, Liu J, Wang G. Niclosamide as a promising therapeutic player in human cancer and other diseases. Int J Mol Sci. 2022;23:16116. https:\/\/doi.org\/10.3390\/ijms232416116.","journal-title":"Int J Mol Sci"},{"key":"1921_CR68","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejpb.2019.05.004","volume":"141","author":"EJ Barbosa","year":"2019","unstructured":"Barbosa EJ, L\u00f6benberg R, de Araujo GLB, Bou-Chacra NA. Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities. Eur J Pharm Biopharm. 2019;141:58\u201369. https:\/\/doi.org\/10.1016\/j.ejpb.2019.05.004.","journal-title":"Eur J Pharm Biopharm"},{"key":"1921_CR69","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1158\/0008-5472.CAN-10-3978","volume":"71","author":"T Osada","year":"2011","unstructured":"Osada T, Chen M, Yang XY, Spasojevic I, Vandeusen JB, Hsu D, et al. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res. 2011;71:4172\u201382. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-3978.","journal-title":"Cancer Res"},{"key":"1921_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-016-3153-x","volume":"5","author":"J Zhao","year":"2016","unstructured":"Zhao J, He Q, Gong Z, Chen S, Cui L. Niclosamide suppresses renal cell carcinoma by inhibiting Wnt\/\u03b2-catenin and inducing mitochondrial dysfunction. SpringerPlus. 2016;5:1436. https:\/\/doi.org\/10.1186\/s40064-016-3153-x.","journal-title":"SpringerPlus"},{"key":"1921_CR71","doi-asserted-by":"publisher","first-page":"42126","DOI":"10.18632\/oncotarget.9704","volume":"7","author":"L Yin","year":"2016","unstructured":"Yin L, Gao Y, Zhang X, Wang J, Ding D, Zhang Y, et al. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt\/\u03b2-catenin signaling. Oncotarget. 2016;7:42126\u201338. https:\/\/doi.org\/10.18632\/oncotarget.9704.","journal-title":"Oncotarget"},{"key":"1921_CR72","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/2211-5463.13817","volume":"14","author":"MY Ng","year":"2024","unstructured":"Ng MY, Song ZJ, Tan CH, Bassetto M, Hagen T. Structural investigations on the mitochondrial uncouplers niclosamide and FCCP. FEBS Open Bio. 2024;14:1057\u201371. https:\/\/doi.org\/10.1002\/2211-5463.13817.","journal-title":"FEBS Open Bio"},{"key":"1921_CR73","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/nm.3699","volume":"20","author":"H Tao","year":"2014","unstructured":"Tao H, Zhang Y, Zeng X, Shulman GI, Jin S. Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice. Nat Med. 2014;20:1263\u20139. https:\/\/doi.org\/10.1038\/nm.3699.","journal-title":"Nat Med"},{"key":"1921_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0092-6","volume":"9","author":"A Alasadi","year":"2018","unstructured":"Alasadi A, Chen M, Swapna GVT, Tao H, Guo J, Collantes J, et al. Effect of mitochondrial uncouplers niclosamide, ethanolamine (NEN), and oxyclozanide on hepatic metastasis of colon cancer. Cell Death Dis. 2018;9:215. https:\/\/doi.org\/10.1038\/s41419-017-0092-6.","journal-title":"Cell Death Dis"},{"key":"1921_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118522","volume":"262","author":"MM Wu","year":"2020","unstructured":"Wu MM, Zhang Z, Tong CWS, Yan VW, Cho WCS, To KKW. Repurposing of niclosamide as a STAT3 inhibitor to enhance the anticancer effect of chemotherapeutic drugs in treating colorectal cancer. Life Sci. 2020;262:118522. https:\/\/doi.org\/10.1016\/j.lfs.2020.118522.","journal-title":"Life Sci"},{"key":"1921_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1761715","volume":"17","author":"Y Zhang","year":"2026","unstructured":"Zhang Y, Cai E. Identifying the therapeutic potential of niclosamide in overcoming IFN-gamma-dependent cancer immune evasion in the tumor microenvironment. Front Immunol. 2026;17:1761715. https:\/\/doi.org\/10.3389\/fimmu.2026.1761715.","journal-title":"Front Immunol"},{"key":"1921_CR77","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.3390\/biom10111493","volume":"10","author":"H Tu","year":"2020","unstructured":"Tu H, Costa M. XIAP\u2019s profile in human cancer. Biomolecules. 2020;10:1493. https:\/\/doi.org\/10.3390\/biom10111493.","journal-title":"Biomolecules"},{"key":"1921_CR78","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.3390\/cancers14205115","volume":"14","author":"S Vivekanandhan","year":"2022","unstructured":"Vivekanandhan S, Knutson KL. Resistance to trastuzumab. Cancers. 2022;14:5115. https:\/\/doi.org\/10.3390\/cancers14205115.","journal-title":"Cancers"},{"key":"1921_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3627-4","volume":"17","author":"AR Hussain","year":"2017","unstructured":"Hussain AR, Siraj AK, Ahmed M, Bu R, Pratheeshkumar P, Alrashed AM, et al. XIAP overexpression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis. BMC Cancer. 2017;17:640. https:\/\/doi.org\/10.1186\/s12885-017-3627-4.","journal-title":"BMC Cancer"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01921-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01921-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01921-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:48:17Z","timestamp":1790088497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01921-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":79,"alternative-id":["1921"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01921-7","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}